ARTICLE | Clinical News
Immunomedics reports Phase I/II metastatic breast cancer data for sacituzumab govitecan
May 18, 2018 2:11 PM UTC
Immunomedics Inc. (NASDAQ:IMMU) said sacituzumab govitecan (IMMU-132) led to an overall response rate (ORR) of 31% in a cohort of 54 patients with estrogen receptor-positive, HER2-negative metastatic breast cancer in the Phase I/II IMMU-132-01 trial. The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago.
All responses were partial responses and all evaluable patients had received at least two prior treatments. In 37 patients who had received prior cyclin dependent kinase (CDK) inhibitors, the ORR was 24%...
BCIQ Target Profiles